Mustang Bio Toekomstige groei

Future criteriumcontroles 0/6

Mustang Bio zal naar verwachting dalen met 19.4% per jaar. De winst per aandeel zal naar verwachting groeien met 108.8% per jaar.

Belangrijke informatie

19.4%

Groei van de winst

108.8%

Groei van de winst per aandeel

Biotechs winstgroei	27.6%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	17 Sep 2024

Recente toekomstige groei-updates

Recent updates

Mustang Bio jumps 7% on encouraging MB-106 safety and efficacy data in blood cancers

Jun 11

Checking Back In On Mustang Bio

May 26

FDA accepts Mustang Bio's MB-106 application in cancer

May 10

Here's Why We're Watching Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation

Mar 22

What Type Of Shareholders Own The Most Number of Mustang Bio, Inc. (NASDAQ:MBIO) Shares?

Feb 23

Mustang Bio, Inc.'s (NASDAQ:MBIO) Intrinsic Value Is Potentially 25% Below Its Share Price

Jan 28

Winst- en omzetgroeiprognoses

NasdaqCM:MBIO - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2025	N/A	-23	N/A	N/A	1
12/31/2024	N/A	-20	N/A	N/A	1
6/30/2024	N/A	-32	-27	-27	N/A
3/31/2024	N/A	-40	-37	-37	N/A
12/31/2023	N/A	-52	-50	-49	N/A
9/30/2023	N/A	-63	-58	-58	N/A
6/30/2023	N/A	-72	-63	-61	N/A
3/31/2023	N/A	-74	-68	-67	N/A
12/31/2022	N/A	-78	-68	-65	N/A
9/30/2022	N/A	-78	-69	-64	N/A
6/30/2022	N/A	-76	-64	-60	N/A
3/31/2022	N/A	-71	-61	-54	N/A
12/31/2021	N/A	-66	-59	-54	N/A
9/30/2021	N/A	-67	-54	-48	N/A
6/30/2021	N/A	-63	-53	-47	N/A
3/31/2021	N/A	-63	-47	-43	N/A
12/31/2020	N/A	-60	-42	-37	N/A
9/30/2020	N/A	-56	-42	-37	N/A
6/30/2020	N/A	-53	-40	-36	N/A
3/31/2020	N/A	-49	-41	-37	N/A
12/31/2019	N/A	-46	-37	-34	N/A
9/30/2019	0	-42	-33	-31	N/A
6/30/2019	0	-39	-29	-26	N/A
3/31/2019	N/A	-34	-28	-20	N/A
12/31/2018	N/A	-31	-27	-19	N/A
9/30/2018	0	-34	-26	-18	N/A
6/30/2018	0	-34	-27	-19	N/A
3/31/2018	N/A	-34	N/A	-16	N/A
12/31/2017	N/A	-31	N/A	-13	N/A
9/30/2017	N/A	-24	N/A	-10	N/A
6/30/2017	N/A	-19	N/A	-6	N/A
3/31/2017	N/A	-15	N/A	-6	N/A
12/31/2016	N/A	-13	N/A	-4	N/A
9/30/2016	N/A	-6	N/A	-3	N/A
6/30/2016	N/A	-5	N/A	-3	N/A
3/31/2016	N/A	-4	N/A	-2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat MBIO de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat MBIO de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat MBIO de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van MBIO naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er wordt verwacht dat MBIO volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van MBIO naar verwachting over 3 jaar hoog zal zijn

Mustang Bio Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 43% to US$10.00

Price target decreased by 29% to US$13.00

Consensus EPS estimates upgraded to US$5.61 loss

Price target decreased by 35% to US$40.75

Consensus EPS estimates fall by 286%

Price target increased by 20% to US$75.00

Recent updates

Listing Qualifications Department of Nasdaq Determines to Delist the Mustang Bio's Securities from Nasdaq

Listing Qualifications Department of Nasdaq Determines to Delist the Mustang Bio's Securities from Nasdaq

New major risk - Market cap size

New major risk - Financial position

New major risk - Market cap size

Mustang Bio, Inc. has filed a Follow-on Equity Offering in the amount of $2.51299 million.

Mustang Bio, Inc. has completed a Follow-on Equity Offering in the amount of $5.6 million.

Mustang Bio, Inc. Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of Mb-106, Cd20-Targeted Autologous Car-T Therapy

New major risk - Shareholder dilution

Mustang Bio Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Price target decreased by 43% to US$10.00

Mustang Bio, Inc. has completed a Follow-on Equity Offering in the amount of $3.998428 million.

New minor risk - Share price stability

Mustang Bio, Inc Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mustang Bio Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Nasdaq Listing Rule 5550(b)(1)

New major risk - Market cap size

Mustang Bio, Inc. has filed a Follow-on Equity Offering in the amount of $10.5 million.

New major risk - Financial position

Mustang Bio, Inc. Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101IL13Ra2-targeted CAR T-Cells in High-Grade Glioma

Mustang Bio, Inc. Appoints Peter Carney as the Interim Chief Accounting Officer

Price target decreased by 29% to US$13.00

Mustang Bio, Inc. announced that it has received $4.742942 million in funding

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Mustang Bio, Inc. Announces FDA Acceptance of IND Application for MB-109, A Novel Combination of MB-101 (IL13RA2-Targeted Car-T Cell Therapy) and MB-108 (HSV-1 Oncolytic Virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Mustang Bio, Inc. Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

uBriGene (Boston) Biosciences Inc. completed the acquisition of Worcester manufacturing facility of Mustang Bio, Inc.

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Consensus EPS estimates upgraded to US$5.61 loss

Price target decreased by 35% to US$40.75

Consensus EPS estimates fall by 286%

Price target increased by 20% to US$75.00

uBriGene (Boston) Biosciences Inc. entered into asset purchase agreement to acquire Worcester manufacturing facility of Mustang Bio, Inc. for $11 million.

Mustang Bio, Inc. Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Price target decreased to US$5.00

Insufficient new directors

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of Mb-106, A First-In-Class Cd20-Targeted, Autologous Car T Cell Therapy to Treat B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Mustang Bio: This Horse May Gallop Still

Is Mustang Bio, Inc. (NASDAQ:MBIO) Trading At A 46% Discount?

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat Rag1 Severe Combined Immunodeficiency

Mustang Bio, Inc. Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy

Mustang Bio Receives Letter from the Listing Qualifications Staff of Nasdaq

Mustang Bio, Inc. Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107

Price target decreased to US$7.40

Mustang Bio, Inc. Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress

Mustang Bio, Inc. Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting

Mustang Bio: The Market Is Missing This Opportunity

Mustang Bio, Inc., Annual General Meeting, Jun 21, 2022

Insufficient new directors

Mustang Bio Inc. Announces Updated Interim Phase 1/2 Data for Mb-106, Cd20-Targeted Car T Therapy, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Mustang Bio, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer

Mustang Bio, Inc. Announces Phase 1 Clinical Trial Combining MB-101 and MB-108 for the Treatment of Glioblastoma

Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency in Previously Transplanted Patients

Price target decreased to US$8.40

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Will Mustang Bio (NASDAQ:MBIO) Spend Its Cash Wisely?

Price target decreased to US$9.80

Mustang Bio Announces MB-101 (IL13Ra2-targeted CAR T cells) Scientific Presentations at Upcoming Virtual Conferences

Mustang Bio: Remains Underfollowed Despite Moving Closer To Pivotal Studies

President recently bought US$251k worth of stock

Mustang Bio, Inc. Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants

Mustang Bio, Inc.(NasdaqGM:MBIO) dropped from Russell 2500 Growth Index

Mustang Bio (MBIO) EHA Investor Presentations - Slideshow

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

Mustang Bio jumps 7% on encouraging MB-106 safety and efficacy data in blood cancers

Checking Back In On Mustang Bio

Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 to Treat Leptomeningeal Brain Tumors

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 2021 Virtual Congress

Mustang Bio, Inc. Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy